NATIONAL RLS OPIOID REGISTRY 4-YEAR DATA UPDATE:

WHAT RLS TREATMENTS ARE REGISTRY PARTICIPANTS USING?


John Winkelman, MD, PhD

Massachusetts General Hospital

Sleep Disorders Clinical Research Program




WHAT **OPIOID MEDICATIONS** ARE REGISTRY PARTICIPANTS TAKING?




8.3% OF PARTICIPANTS TAKE A COMBINATION OF TWO OPIOID MEDICATIONS

WHAT **OTHER RLS MEDICATIONS** ARE REGISTRY PARTICIPANTS TAKING?




Calcium Channel Ligands




HOW DO REGISTRY PARTICIPANTS COMBINE THEIR MEDICATIONS?

While many participants manage their RLS with the use of opioids alone, 50% of participants use an additional medication (or two) to manage their symptoms.




DO REGISTRY PARTICIPANTS USE **CBD OR THC** AS RLS TREATMENTS?



WHICH REGISTRY PARTICIPANTS USE **THC** TO TREAT THEIR RLS?

Where do THC users live?



Compared to the overall Registry, those that use THC for their RLS...

- Have similar age and sex distribution
- Have a higher median opioid dose
- Have slightly more severe RLS

State of residence may be a barrier to those willing to try THC to treat their RLS

Thank you for your continued participation!

Response Rate:

1-Year: 2-Year: 3-Year: 4-Year: 97.7% 94.9% 94.4% 93.6%

Nearly all still-eligible participants enrolled at baseline (93.6%) continue to participate.

Recent Descriptions of Registry Findings:

- Presentation at World SLEEP 2023 (Rio de Janeiro)
- Article in Nightwalkers Fall 2023

This study is not meant to be used as clinical guidance nor is it a reflection of individual experiences.

Questions or comments? Please email akilty@mgh.harvard.edu or call (617) 643 - 6026

500 Total at Baseline

441 Completed 3-Year

425 Completed 4-Year

276 Completed 5-Year So Far